Health Catalyst, Inc.
HCAT$259M
Micro CapNASDAQServices-Computer Programming, Data Processing, Etc.🇺🇸North AmericaSOUTH JORDAN1.5K employees
Drugs in Pipeline
7
Phase 3 Programs
7
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
HCAT News
Catalyst Timeline
0 upcoming, 0 past
No catalysts found.
Drug Pipeline
Budesonide
Colitis, Ulcerative
Plecanatide
Chronic Idiopathic Constipation
Rifaximin
Hepatic Encephalopathy
Methylnaltrexone
Post-Operative Ileus (POI)
Crofelemer
HIV Enteropathy
MOA-728
Ileus
N-methylnaltrexone bromide (MOA-728)
Constipation
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Budesonide | Phase 3 | Colitis, Ulcerative | - | - |
Plecanatide | Phase 3 | Chronic Idiopathic Constipation | - | - |
Rifaximin | Phase 3 | Hepatic Encephalopathy | - | - |
Methylnaltrexone | Phase 3 | Post-Operative Ileus (POI) | - | - |
Crofelemer | Phase 3 | HIV Enteropathy | - | - |
MOA-728 | Phase 3 | Ileus | - | - |
N-methylnaltrexone bromide (MOA-728) | Phase 3 | Constipation | - | - |
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply